Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Next Previous
Trial Profile

A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; PRT 3789 (Primary)
  • Indications Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prelude Therapeutics

Most Recent Events

  • 29 May 2025 Planned initiation date (estimated date of first participant enrollement) changed from 1 May 2025 to 1 Jun 2025.
  • 01 May 2025 Planned initiation date (estimated date of first participant enrollement) changed from 1 Apr 2025 to 1 May 2025.
  • 30 Mar 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top